This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou +6 more
wiley +1 more source
Structural and Computational Insights into the Angiotensin II Type 1 Receptor: Advances in Antagonist Design and Implications for Hypertension Therapy (2020-2024). [PDF]
Chatzipieris FP +4 more
europepmc +1 more source
ABSTRACT The scope, organization, and biological significance of innate immune functions across structural cell types remain poorly defined. To address these fundamental knowledge gaps, we analyzed experimental data of transcriptomes generated by our group and others.
Juanjuan Liu +22 more
wiley +1 more source
Astrocyte-Neuron Crosstalk in Hypertension: Mechanisms and Therapeutic Significance. [PDF]
Zhao M, Jia H, Li N.
europepmc +1 more source
Advances in the Treatment of Autosomal Dominant Polycystic Kidney Disease and Novel Therapeutic Targets. [PDF]
Zhang W, Sun T, Wang X, Jiang T.
europepmc +1 more source
Characterization of elevated levels of endometrial renin-angiotensin system components suggest a role in endometrial repair. [PDF]
Symington TL +6 more
europepmc +1 more source
The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension. [PDF]
Masi S +7 more
europepmc +1 more source
The role of IP<sub>3</sub>R and TRPC3 channels in vasoconstriction and hypertension. [PDF]
Moraes RDA +4 more
europepmc +1 more source
The Cardioprotective Potential of Marine Venom and Toxins. [PDF]
Siagian VHM, Nuwarda RF.
europepmc +1 more source

